Provided is a method for producing taurine including: providing a reaction solution comprising alkali metal taurinate and/or alkali metal isethionate, passing at least a portion of the reaction solution through a column of basic anion exchange resin, adsorbing anions of alkali metal taurinate and/or alkali metal isethionate to the basic anion exchange resin, and collecting an eluate comprising at least one impurity, desorbing anions of alkali metal taurinate and/or alkali metal isethionate from the basic anion exchange resin with an alkaline solution, and collecting a desorption liquid comprising alkali metal taurinate and/or alkali metal isethionate, subjecting the desorption liquid comprising alkali metal taurinate to acidification or subjecting the desorption liquid comprising alkali metal isethionate to aminolysis and acidification, thereby obtaining taurine.

Provided is a method for producing taurine including: providing a reaction solution comprising alkali metal taurinate and/or alkali metal isethionate, passing at least a portion of the reaction solution through a column of basic anion exchange resin, adsorbing anions of alkali metal taurinate and/or alkali metal isethionate to the basic anion exchange resin, and collecting an eluate comprising at least one impurity, desorbing anions of alkali metal taurinate and/or alkali metal isethionate from the basic anion exchange resin with an alkaline solution, and collecting a desorption liquid comprising alkali metal taurinate and/or alkali metal isethionate, subjecting the desorption liquid comprising alkali metal taurinate to acidification or subjecting the desorption liquid comprising alkali metal isethionate to aminolysis and acidification, thereby obtaining taurine.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

A N-acylated taurine composition comprising: (a) a first N-acylated taurine compound of the formula (IA) or a salt thereof:

##STR00001## and (b) a second N-acylated taurine compound of the formula (IB) or a salt thereof:

##STR00002## wherein R.sup.1a and R.sup.2a are C.sub.1-4 alkyl, wherein R.sup.1a and R.sup.2a are the same; R.sup.3 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.1-6 alkyl substituted with an aryl group; and R.sup.4 is C.sub.4-25 alkyl or C.sub.4-25 alkenyl, wherein the C.sub.4-25 alkyl or C.sub.4-25 alkenyl is optionally substituted by hydroxy.

A N-acylated taurine composition comprising: (a) a first N-acylated taurine compound of the formula (IA) or a salt thereof:

##STR00001## and (b) a second N-acylated taurine compound of the formula (IB) or a salt thereof:

##STR00002## wherein R.sup.1a and R.sup.2a are C.sub.1-4 alkyl, wherein R.sup.1a and R.sup.2a are the same; R.sup.3 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.1-6 alkyl substituted with an aryl group; and R.sup.4 is C.sub.4-25 alkyl or C.sub.4-25 alkenyl, wherein the C.sub.4-25 alkyl or C.sub.4-25 alkenyl is optionally substituted by hydroxy.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Psilocin formulations of psilocin mucate with improved stability, physical properties and/or handling characteristics, as well as enhanced pharmacologic activity, pharmacokinetic parameters and safety characteristics as compared to psilocin or psilocybin and methods for their use are provided.

The present application in some embodiments provides a pharmaceutical composition comprising:

##STR00001## and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.